RoboMed Oy and FasterCapital Equitypilot Partner to Fast‑Track Robotic Capsule for Real‑Time Wireless Endoscopy
Helsinki, Finland & Dubai, UAE - Oct 21, 2025
RoboMed Oy and FasterCapital announced today a strategic partnership through FasterCapital’s Equitypilot program to accelerate commercialization of RoboMed’s robotic capsule for real‑time wireless endoscopy and in‑vivo biopsy. The collaboration targets global markets — beginning in the Nordics and EU — to address urgent diagnostic gaps in small‑intestine disease detection via technology, funding, regulatory and go‑to‑market support.
Market Opportunity & Problem
The global endoscopy and gastrointestinal biopsy markets together represent tens of billions in annual spend and are growing with an aging population and rising GI disease incidence. Traditional tethered endoscopy and passive capsule systems leave much of the small intestine under‑examined, delaying diagnoses for conditions such as colorectal cancer, Crohn’s disease and celiac disease. Existing devices are limited by passive locomotion, offline image retrieval and lack of live biopsy capability, creating a clear white space for a minimally invasive, real‑time diagnostic platform.
Startup Solution & Differentiation
RoboMed’s robotic capsule uniquely combines high‑resolution, real‑time video streaming, six deployable micro‑needles for targeted biopsy, and cloud‑enabled diagnostics with VR/AR visualization and AI‑assisted image prioritization. The company holds a Finnish patent and an international PCT filing, with prototypes validated in lab and preclinical tests and plans to advance clinical evaluation in 2025. By integrating live biopsy control through a smartphone app and synchronized VR/AR interfaces, RoboMed addresses physician workflow, patient comfort and remote diagnostics in underserved regions — features not available in current market offerings.
FasterCapital Partnership Value
Under FasterCapital’s Equitypilot program, RoboMed will receive tailored acceleration services: strategic fundraising support, regulatory and CE/MDR advisory, go‑to‑market channel development, and access to FasterCapital’s global investor network. FasterCapital’s selective criteria and track record of scaling deep‑tech healthcare startups validate RoboMed’s technology and market fit. The partnership is structured to catalyze RoboMed’s seed raise (target: €2M) and compress time‑to‑market via regulatory and commercialization roadmaps.
Executive Quotes
“Hesham Zreik, CEO of FasterCapital, said: “RoboMed’s capsule addresses a defining gap in gastrointestinal diagnostics — combining real‑time imaging with live biopsy and remote operability. Equitypilot selects companies with differentiated IP, clinical promise and scalable business models; RoboMed meets all three. We look forward to enabling their next phase of regulatory, clinical and commercial scale‑up.””
“Yaser Sabzehmeidani, Founder & COB of RoboMed Oy, said: “This partnership accelerates our mission to make early GI diagnosis accessible and less invasive. FasterCapital’s resources and mentorship will help us finalize clinical validation, secure CE/FDA pathways, and deploy our capsule into hospitals and telemedicine networks worldwide.””
Growth Trajectory & Future Plans
Near‑term priorities include completing clinical studies, CE/MDR conformity, production scale‑up and a seed round in late 2025. RoboMed’s five‑year plan targets commercial sales across Europe and export markets, a multi‑channel B2B/B2B2C model with hospitals, clinics and governments, and achieving meaningful market share by 2030. Long term, RoboMed aims to extend the platform for drug delivery, microbiota sampling and broader GI therapeutic applications.
About RoboMed Oy
RoboMed Oy is a Helsinki‑based medtech company developing a robotic capsule for endoscopy, biopsy and microbiota sampling of the small intestine. Founded in 2020, RoboMed’s mission is to advance non‑invasive diagnostics and improve early disease detection with assistive robotics and digital medicine.
About FasterCapital
FasterCapital is a global technology accelerator and early‑stage investor focused on scaling deep‑tech and software startups. Its Equitypilot program provides capital formation, technical resources, regulatory guidance and market entry support to high‑potential ventures.